OrthoPediatrics Past Earnings Performance

Past criteria checks 0/6

OrthoPediatrics has been growing earnings at an average annual rate of 5.2%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 21.3% per year.

Key information

5.2%

Earnings growth rate

13.8%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate21.3%
Return on equity-7.7%
Net Margin-15.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How OrthoPediatrics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2X7 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24190-2815810
30 Jun 24175-2514710
31 Mar 24162-2213611
31 Dec 23149-2112710
30 Sep 23142-2212110
30 Jun 23137111610
31 Mar 2313041108
31 Dec 2212211048
30 Sep 221169998
30 Jun 22106-12937
31 Mar 22100-15886
31 Dec 2198-16866
30 Sep 2192-30816
30 Jun 2189-33806
31 Mar 2176-38745
31 Dec 2071-33705
30 Sep 2071-23665
30 Jun 2070-22635
31 Mar 2074-15606
31 Dec 1973-13576
30 Sep 1968-11535
30 Jun 1963-10495
31 Mar 1960-10485
31 Dec 1858-12485
30 Sep 1855-25484
30 Jun 1851-26464
31 Mar 1848-26424
31 Dec 1746-24373
30 Sep 1743-14323
30 Jun 1741-13312
31 Mar 1739-12292
31 Dec 1637-12282
31 Mar 1633-12282
31 Dec 1531-13262
31 Dec 1424-13222

Quality Earnings: 2X7 is currently unprofitable.

Growing Profit Margin: 2X7 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2X7 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.

Accelerating Growth: Unable to compare 2X7's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2X7 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 2X7 has a negative Return on Equity (-7.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 17:29
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OrthoPediatrics Corp. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
David TurkalyJMP Securities
Jonathan BraatzKansas City Capital Associates